Lp(a)'s Odyssey: Should We Measure Lp(a) Post-ACS and What Should We Do With the Results?
- PMID: 31948642
- DOI: 10.1016/j.jacc.2019.11.016
Lp(a)'s Odyssey: Should We Measure Lp(a) Post-ACS and What Should We Do With the Results?
Keywords: acute coronary syndromes; alirocumab; low-density lipoprotein cholesterol; major adverse cardiovascular events; proprotein convertase subtilisin/kexin type 9 inhibition.
Comment on
-
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.J Am Coll Cardiol. 2020 Jan 21;75(2):133-144. doi: 10.1016/j.jacc.2019.10.057. J Am Coll Cardiol. 2020. PMID: 31948641 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous